Search results for "bladder"

showing 10 items of 628 documents

Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results

2019

Abstract Background Preclinical biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy of bone metastases. We evaluated biodistribution and normal organ absorbed doses resulting from therapeutic doses of [177Lu]Lu-DOTAZOL in patients with metastatic skeletal disease. Method Four patients with metastatic skeletal disease (age range, 64–83 years) secondary to metastatic castration-resistant prostate carcinoma or bronchial carcinoma were treated with a mean dose of 5968 ± 64 MBq (161.3 mCi) of [177Lu]Lu-DOTAZOL. Biodistribution was assessed with serial planar whole body scintigraphy at 20 min and 3,…

lcsh:Medical physics. Medical radiology. Nuclear medicine[177Lu]Lu-DOTAZOLBiodistributionKidneyUrinary bladderbusiness.industrymedicine.medical_treatmentlcsh:R895-920Organ absorbed dosesBone metastasisBisphosphonatemedicine.diseaseProstate carcinomamedicine.anatomical_structureAbsorbed doseRadionuclide therapymedicineRadiology Nuclear Medicine and imagingBone marrowBronchial carcinomabusinessNuclear medicineBone seeking therapeutic radionuclidesOriginal ResearchEJNMMI Research
researchProduct

Mutant HRAS as novel target for MEK and mTOR inhibitors.

2015

HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an imp…

mTOR inhibitorMutantBlotting Western610 Medicine & healthApoptosisMice SCIDCell LineProto-Oncogene Proteins p21(ras)chemistry.chemical_compoundCell Line TumorNeoplasmsMedicineAnimalsHumansHRASHRAS mutationsProtein Kinase InhibitorsPI3K/AKT/mTOR pathwayCell ProliferationGeneticsMitogen-Activated Protein Kinase KinasesMEK inhibitorOncogeneCell growthbusiness.industryMEK inhibitorTOR Serine-Threonine KinasesDiphenylamineXenograft Model Antitumor AssaysTumor Burdenlung cancer10219 Clinic for Gastroenterology and HepatologyCell Transformation NeoplasticOncologychemistry10032 Clinic for Oncology and HematologyBenzamidesMutationCancer researchbladder cancer2730 OncologyBenzimidazolesRNA InterferenceSignal transductionGrowth inhibitionbusinessSignal TransductionResearch PaperOncotarget
researchProduct

Mirizzi syndrome type V complicated with both cholecystobiliary and cholecystocolic fistula: a case report

2021

Abstract Mirizzi syndrome (MS) is a common bile duct (CBD) obstruction caused by extrinsic compression from an impacted stone in the cystic duct or infundibulum of the gallbladder. Patients affected by MS may present abdominal pain and jaundice. A 37-year-old male with neurologic residuals post-encephalitis arrived at the emergency department reporting abdominal pain, jaundice and fever. An ultrasound of the abdomen identified cholecystolithiasis with a dilated CBD. He did not undergo CT or MRI due to poor compliance and parents’ disagreement. Eventually, they accepted to perform endoscopic retrograde cholangiopancreatography, which diagnosed MS with both cholecystobiliary and cholecystocol…

medicine.medical_specialtyAbdominal painAcademicSubjects/MED00910medicine.medical_treatmentCase Report03 medical and health sciences0302 clinical medicinejscrep/080medicine030212 general & internal medicineMirizzi's syndromeEndoscopic retrograde cholangiopancreatographyCommon bile ductmedicine.diagnostic_testbusiness.industryGallbladderJaundicemedicine.diseaseSurgerymedicine.anatomical_structureCystic duct030211 gastroenterology & hepatologySurgeryCholecystectomymedicine.symptombusinessJournal of Surgical Case Reports
researchProduct

A temporary endoscopic solution that significantly improves the prognosis of Bouveret’s syndrome

1991

We report the case of a 73-year-old woman who was hospitalized for mild abdominal pain after her referral following a diagnostic assessment of acute lithiasic cholecystitis. After the spontaneus regression of her painful symptoms and fever and several days of well-being, her clinically acute abdominal features suddenly showed an obstruction of the upper gastrointestinal tract. An emergency esophagogastroduodenoscopy (EGDS) confirmed that a large gallstone completely obstructed the pylorus as previously demonstrated by an ultrasound examination of the gallbladder. During the course of endoscopy, removal of the gallstone from the duodenum was achieved by pulling it into the stomach; the patie…

medicine.medical_specialtyAbdominal painTime FactorsEndoscopy GastrointestinalPyloric StenosisPyloric stenosisCholelithiasisHumansMedicineAgedmedicine.diagnostic_testbusiness.industryEsophagogastroduodenoscopyGallbladderSyndromePrognosismedicine.diseasePylorusSurgeryEndoscopymedicine.anatomical_structureCholecystitisFemaleSurgerymedicine.symptombusinessAbdominal surgerySurgical Endoscopy
researchProduct

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

2007

Abstract Antimuscarinic therapy is the primary treatment for overactive bladder. Long-term persistence with the therapy can be problematical, and has been linked to both efficacy and tolerability. A number of specific contributory factors to poor persistence can be identified, such as adverse effects of medication, insufficient beneficial effects, inadequate follow-up after initiation of therapy (poor motivation), and unmet or unrealistic expectations (poor communication between the patient and physician). Open-label studies on antimuscarinics overestimate the real-life persistence, which can lead to unrealistic expectations of the physician. Dose flexibility has improved patient compliance…

medicine.medical_specialtyAntimuscarinic Agentbusiness.industryTransdermal patchUrologymedicine.diseasePatient satisfactionTolerabilityQuality of lifeOveractive bladderPillPhysical therapyMedicineAdverse effectbusinessIntensive care medicineEuropean Urology Supplements
researchProduct

Comparison between Two Different Two-Stage Transperineal Approaches to Treat Urethral Strictures or Bladder Neck Contracture Associated with Severe U…

2012

Introduction.The recurrence of urethral/bladder neck stricture after multiple endoscopic procedures is a rare complication that can follow prostatic surgery and its treatment is still controversial.Material and Methods.We retrospectively analyzed our data on 17 patients, operated between September 2001 and January 2010, who presented severe urinary incontinence and urethral/bladder neck stricture after prostatic surgery and failure of at least four conservative endoscopic treatments. Six patients underwent a transperineal urethrovesical anastomosis and 11 patients a combined transperineal suprapubical (endoscopic) urethrovesical anastomosis. After six months the patients that presented comp…

medicine.medical_specialtyArticle SubjectUrethral stricturebusiness.industryUrologyUrethral sphincterBladder neck contractureObstetrics and GynecologyLumen (anatomy)Urinary incontinenceAnastomosislcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923medicine.diseaseSurgeryNeck of urinary bladderClinical StudymedicineProstatectomy | Constriction Pathologic | neck contracturemedicine.symptomComplicationbusinessAdvances in Urology
researchProduct

Asymptotic modeling of electrochemical signaling: Testing Zn in urine for non-invasive bladder cancer diagnosis

2021

Abstract A theoretical model on chemical signaling for diagnosis based on the combination of signals for marker and inert and/or interfering metabolites is described. The model yields asymptotic relationships between the intensities of the signals representative of marker and accompanying metabolites compensating concentration fluctuations. The model fits well with voltammetric features associated to the oxidation of different urine metabolites and Zn(II) reduction in the same urine samples after alkaline digestion. As a result, a non-invasive electrochemical detection of urothelial carcinoma (bladder cancer, BC) is reported. Different diagnostic criteria are described all displaying high s…

medicine.medical_specialtyBladder cancerChemistryUrinary systemBladder cancerNon invasiveChemical signalingMetals and AlloysUrologyNon-invasive diagnosticElectrochemical detectionUrineUrineCondensed Matter Physicsmedicine.diseasePredictive valueSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsZincElectrochemistryMaterials ChemistrymedicineElectrical and Electronic EngineeringInstrumentationUrothelial carcinomaSensors and Actuators B: Chemical
researchProduct

MP26-19 A PROSPECTIVE STUDY ON THE INFLUENCE ON RECURRENCE OF QUITTING CIGARETTE SMOKING AT DIAGNOSIS OF PRIMARY NON MUSCLE INVASIVE BLADDER CANCER

2015

medicine.medical_specialtyBladder cancerCigarette smokingbusiness.industryUrologyInternal medicinemedicineNon muscle invasiveProspective cohort studybusinessmedicine.diseaseSurgeryJournal of Urology
researchProduct

T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do!

2009

“How many roads a man must walk on….” and how many papers we must read and write… to put down the final word on the appropriate management of high risk NMI-BC. Although it is more than 20 years that we take notice of promises on biological markers predictive of the behaviour of NMI-BC, till today we can only base our decisions on clinical and pathological data. Consequently, we need exchange of experiences and reports on the outcome of these patients. The aim of the treatment of T1 bladder tumours is to minimize mortality while assuring reduced morbidity and good quality of life. A conservative approach is, obviously, not applicable to all T1HG tumours. We need to identify unequivocal selec…

medicine.medical_specialtyBladder cancerNoticebusiness.industryUrologyGeneral surgerymedicine.diseaseResectionQuality of lifeConcomitantBladder cancer T1 high grade G3 cystectomy conservative treatmentmedicineProper treatmentProgression ratebusinessEuropean Urology
researchProduct

Intravesical instillation of adriamycin in treatment of bladder cancer

1984

medicine.medical_specialtyBladder cancerbusiness.industryUrologyIntravesical instillationUrologymedicinemedicine.diseasebusinessUrology
researchProduct